Trimeris names new CEO
Executive Summary
Former GlaxoSmithKline Senior VP-Global Commercial Strategy Steven Skolsky takes top leadership slot at Trimeris effective Sept. 9. Skolsky succeeds company founder Dani Bolognesi, PhD, who is staying on as chief scientific officer. Skolsky's appointment fills a need for senior leadership following the departure of Trimeris' President Nixon Ellis, PhD, in June. At GSK, Skolsky's most recent post is being filled by Richard Wallace, who moved up from VP-global therapeutic area strategy for psychiatry...
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.